TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35504634

Group type: EXPERIMENTAL
Intervention: Temporary interruption of low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster
Number of subjects: 560

Group type: COMPARATOR
Intervention: Usual care (continuing low-dose methotrexate treatment)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Temporary interruption of low-dose methotrexate treatment
Number of subjects: 560
Study: 33914964

Group type: EXPERIMENTAL
Intervention: FIFA 11+ Referees Program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual warm-ups (Control)
Number of subjects: 200
Study: 91276441

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg twice a day for three weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 35835920

Group type: EXPERIMENTAL
Intervention: Group A (extracorporeal interrupted 0 delayed absorbable sutures)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B (U-shaped running locked 0 delayed absorbable suture)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study: 33012083

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus Sirolimus (Tac/Sir)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Cyclosporine plus Methotrexate (CsA/Mtx)
Number of subjects: 141
Study: 36401662

Group type: EXPERIMENTAL
Intervention: Beetroot juice (70 mL, 6.4 mmol NO3−)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (70 mL, 0.04 mmol NO3−)
Number of subjects: 11
Study: 35397572

Group type: EXPERIMENTAL
Intervention: Bacillus clausii (oral suspension of 2 billion spores per 5 mL bottle) plus oral rehydration therapy (ORT) and zinc
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo plus oral rehydration therapy (ORT) and zinc
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 35594726

Group type: EXPERIMENTAL
Intervention: Body positive social media content
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Thin-and-toned ideal social media content
Number of subjects: 261

Group type: COMPARATOR
Intervention: Neutral travel condition
Number of subjects: 261
Study: 32156239

Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thiopental (4 mg/kg) + Ketamine (0.5 mg/kg)
Number of subjects: 100
Study: 32171439

Group type: EXPERIMENTAL
Intervention: Supervised exercise training 3 times/week for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (usual care and counseling)
Number of subjects: 30
Study: 36219460

Group type: EXPERIMENTAL
Intervention: Hydrogel enriched with sodium alginate and vitamins A and E
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (cleaning and a simple dressing)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydrogel treatment
Number of subjects: 26
Study: 33492010

Group type: EXPERIMENTAL
Intervention: Bandage contact lens (BCL) exchange on the first postoperative day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (BCL not exchanged)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: A-PRK
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Trans-PRK
Number of subjects: 56
Study: 34898074

Group type: EXPERIMENTAL
Intervention: Luobufukebiri Pills (LP), 10 pills bid for 12 weeks
Number of subjects: 206

Group type: COMPARATOR
Intervention: Vitamin E soft capsules, 100 mg bid for 12 weeks
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Luobufukebiri Pills (LP) vs Vitamin E soft capsules
Number of subjects: 206
Study: 36344978

Group type: EXPERIMENTAL
Intervention: Multifactorial intensive treatment
Number of subjects: 317

Group type: COMPARATOR
Intervention: High-risk group (4 risk factors)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Intermediate risk group (2-3 risk factors)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Absent/low risk group (0-1 risk factor)
Number of subjects: 317
Study: 35717146

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (90-minute weekly sessions for 6 weeks plus two booster sessions)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 800
Study: 32200410

Group type: EXPERIMENTAL
Intervention: Expert surgeon (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Expert E-BLUS tutor (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: E-BLUS guide alone (group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No tutor (group 4)
Number of subjects: 60
Study: 2005275508

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 30
Study: 33567460

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment with Bryonia alba (33.3%), Arsenicum album (18.1%), Pulsatilla nigricans (13.8%), Nux vomica (8%), Rhus toxicodendron (7.2%), Gelsemium sempervirens (5.8%) in 30C potency
Number of subjects: 196

Group type: COMPARATOR
Intervention: Conventional treatment (details not specified)
Number of subjects: 196
Study: 33175003

Group type: EXPERIMENTAL
Intervention: Dental trauma (specifically avulsion)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Caries experience
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Income
Number of subjects: 571
Study: 35342994

Group type: COMPARATOR
Intervention: CoQ10 phytosome acute supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: CoQ10 phytosome middle-term supplementation
Number of subjects: 20
Study: 33658007

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic management (maintaining stroke volume variation < 6%, cardiac index 3.0-4.0 L/min/m2, mean arterial pressure > 95 mmHg with crystalloid fluids and infusion of dobutamine and/or norepinephrine)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine hemodynamic management (control group)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic management
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine hemodynamic management
Number of subjects: 144
Study: 32028833

Group type: EXPERIMENTAL
Intervention: I3C/PROVE IT!
Number of subjects: 237

Group type: COMPARATOR
Intervention: business-as-usual
Number of subjects: 237
Study: 36055329

Group type: EXPERIMENTAL
Intervention: Short treatment with a carbapenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended treatment with a carbapenem
Number of subjects: 0
Study: 33575989

Group type: EXPERIMENTAL
Intervention: Intravenous Methylprednisolone (IVMP) 30 mg/kg/d for 3 days followed by oral prednisolone taper
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous Methylprednisolone (IVMP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral Prednisolone (OP) 4 mg/kg/d for two weeks followed by taper
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral Prednisolone (OP)
Number of subjects: 60
Study: 36017797

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (3.5 mg/kg, approved dose)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo (dummy pill)
Number of subjects: 870
Study: 36029412

Group type: EXPERIMENTAL
Intervention: ipilimumab 3 mg/kg (ipi3)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: ipilimumab 10 mg/kg (ipi10)
Number of subjects: 549

Group type: COMPARATOR
Intervention: high-dose interferon (HDI)
Number of subjects: 549
Study: 33616033

Group type: EXPERIMENTAL
Intervention: Educational outreach group (n = 32)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait list control group (n = 39)
Number of subjects: 71
Study: 32324651

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADL) treatment
Number of subjects: 66
Study: 34407734

Group type: EXPERIMENTAL
Intervention: Lemna protein concentrate (LPC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Whey protein concentrate (WPC)
Number of subjects: 12
Study: 33512814

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block with 20 mL 0.5% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local infiltration analgesia using Ranawat cocktail (60 mL applied to subacromial space and glenohumeral joint)
Number of subjects: 60
Study: 32387225

Group type: EXPERIMENTAL
Intervention: His Bundle Pacing (HBP)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Pacing (LBBP)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Biventricular Pacing (BVP)
Number of subjects: 137
Study: 36037698

Group type: EXPERIMENTAL
Intervention: Yoga practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no yoga practice)
Number of subjects: 0
Study: 34636255

Group type: EXPERIMENTAL
Intervention: T-DM1 + tucatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: T-DM1 + placebo
Number of subjects: 0
Study: 33909203

Group type: EXPERIMENTAL
Intervention: Neratinib + capecitabine (N + C)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Lapatinib + capecitabine (L + C)
Number of subjects: 621
Study: 34973707

Group type: EXPERIMENTAL
Intervention: RF toothbrush (ToothWave, Home Skinovations)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sonic vibrating toothbrush (SmileSonic powered toothbrush, Ranir)
Number of subjects: 86
Study: 34103270

Group type: EXPERIMENTAL
Intervention: Community Midwifery Program (CMP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Midwifery Antenatal Care (MAC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 221
Study: 32523546

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) use
Number of subjects: 53

Group type: COMPARATOR
Intervention: Naturally hormonally cycling (AthletesNC)
Number of subjects: 53
Study: 33539256

Group type: EXPERIMENTAL
Intervention: Lidocaine in-situ gel
Number of subjects: 216
Study: 33041263

Group type: EXPERIMENTAL
Intervention: SYNAP exercise group (SG, n=15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG, n=9)
Number of subjects: 24
Study: 36128174

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) in the experimental group (neoadjuvant chemotherapy + surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT examination in the experimental group (neoadjuvant chemotherapy + surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic ultrasonography (EUS) in the control group (conventional surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT examination in the control group (conventional surgery)
Number of subjects: 0
Study: 33051083

Group type: EXPERIMENTAL
Intervention: Lowest postoperative haemoglobin concentration <110 g L−1
Number of subjects: 7227

Group type: EXPERIMENTAL
Intervention: Postoperative haemoglobin concentrations <88 g L−1
Number of subjects: 7227

Group type: EXPERIMENTAL
Intervention: Postoperative haemoglobin concentrations >113 g L−1
Number of subjects: 7227

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 7227

Group type: COMPARATOR
Intervention: Patients with lowest postoperative haemoglobin concentration >110 g L−1
Number of subjects: 7227
Study: 34597534

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 96 weeks
Number of subjects: 2282

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 148 weeks (subgroup analysis)
Number of subjects: 2282
Study: 32516486

Group type: EXPERIMENTAL
Intervention: IVR-T intervention
Number of subjects: 295

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 295
Study: 37561251

Group type: EXPERIMENTAL
Intervention: 0.1% FML eye drops once every half hour (Group C)
Number of subjects: 180

Group type: COMPARATOR
Intervention: 0.1% FML eye drops once every hour (Group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No FML (Group A)
Number of subjects: 180
Study: 34368943

Group type: EXPERIMENTAL
Intervention: Sublingual (SL) 50 mg ketamine lozenge
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral (PO) 50 mg ketamine lozenge
Number of subjects: 23

Group type: COMPARATOR
Intervention: SL placebo lozenge
Number of subjects: 23

Group type: COMPARATOR
Intervention: PO placebo lozenge
Number of subjects: 23
Study: 32540886

Group type: EXPERIMENTAL
Intervention: Two approaches to improving Lynch syndrome detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation Leads and Lynch syndrome stakeholders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team meetings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fidelity checklists and project log analysis
Number of subjects: 0
Study: 33884453

Group type: EXPERIMENTAL
Intervention: Double coraco‐clavicular tunnel technique in an anatomical configuration (DCTa)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Double coraco‐clavicular tunnel technique in an inverse configuration of the anatomical position (DCTb)
Number of subjects: 13
Study: 33031349

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 759

Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation
Number of subjects: 759
Study: 32692244

Group type: EXPERIMENTAL
Intervention: Propofol at 2.310 mg/kg (EC50) in group B
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol at 3.567 mg/kg (EC50) in group M
Number of subjects: 40
Study: 34895775

Group type: EXPERIMENTAL
Intervention: Language-concordant health coaching intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 36171989

Group type: EXPERIMENTAL
Intervention: 1MSTSIND (individually adapted seat height to 90° knee flexion)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 1MSTSSTD (standard chair seat height of 46 cm)
Number of subjects: 49
Study: 33297967

Group type: EXPERIMENTAL
Intervention: Dementia care toolbox (including patient brochures, information cards, and posters) mailed to GP practices.
Number of subjects: 50
Study: 36346279

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 34819447

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: NSAIDs + Diacerein
Number of subjects: 72
Study: 32142514

Group type: EXPERIMENTAL
Intervention: Text messaging intervention for smoking cessation over 12 weeks
Number of subjects: 535

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 535
Study: 33930277

Group type: EXPERIMENTAL
Intervention: High pressure (100% resting limb occlusion pressure, 20% one-repetition maximum)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate pressure (50% resting limb occlusion pressure, 20% one-repetition maximum)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional resistance training (TRT; 70% one-repetition maximum)
Number of subjects: 20
Study: 33332416

Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire (FFQ) for marine n-3FA consumption
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Plasma phospholipid (PL) marine n-3FA levels
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Correlation between FFQ estimates and plasma PL marine n-3FA levels
Number of subjects: 132
Study: 32202181

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training plus supervised spinal mobility exercises, 3 days a week for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Supervised spinal mobility exercises only, 3 times a week for 12 weeks
Number of subjects: 31
Study: 35466101

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combination treatment (NAC and nutraceuticals)
Number of subjects: 148
Study: 33470329

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAPT) - aspirin, ticagrelor, and tirofiban
Number of subjects: 162

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) - aspirin and ticagrelor
Number of subjects: 162
Study: 34897103

Group type: EXPERIMENTAL
Intervention: rTMS‐VR group
Number of subjects: 40

Group type: COMPARATOR
Intervention: rTMS group
Number of subjects: 40
Study: 32340846

Group type: EXPERIMENTAL
Intervention: 3-dimensional printing templates for cervical lateral mass screw insertion (Group A)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Freehand technique for cervical lateral mass screw insertion (Group B)
Number of subjects: 6
Study: 35149905

Group type: EXPERIMENTAL
Intervention: Irradiated root dentin with conventional resin cement (RelyX ARC, 3 M ESPE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irradiated root dentin with self-adhesive resin cement (RelyX U200, 3 M ESPE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-irradiated root dentin with conventional resin cement (RelyX ARC, 3 M ESPE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-irradiated root dentin with self-adhesive resin cement (RelyX U200, 3 M ESPE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irradiated root dentin
Number of subjects: 40
Study: 35470190

Group type: EXPERIMENTAL
Intervention: SPACE FOR COPD programme (home-based manual and 4, 2-hour group sessions over 12 months)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: SPACE FOR COPD programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study: 34693756

Group type: EXPERIMENTAL
Intervention: 3-min bouts of light-intensity walking every 30 min of sitting (BR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30-min bout of moderate-to-vigorous exercise followed by prolonged sitting (EX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Prolonged sitting (SIT)
Number of subjects: 15
Study: 35427205

Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lenvima® 10 mg
Number of subjects: 100
Study: 34129720

Group type: EXPERIMENTAL
Intervention: Achieving ≥7 critical care endpoints
Number of subjects: 6052

Group type: EXPERIMENTAL
Intervention: Donor blood pH
Number of subjects: 6052

Group type: EXPERIMENTAL
Intervention: Administration of dopamine during donor management
Number of subjects: 6052

Group type: EXPERIMENTAL
Intervention: Tidal volumes ≤8 ml/kg predicted body weight
Number of subjects: 6052

Group type: EXPERIMENTAL
Intervention: Higher positive end-expiratory pressures
Number of subjects: 6052
Study: 32544575

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HFRT) - 40 Gy/15 fractions, 45 Gy/15 fractions, 45 Gy/20 fractions
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventionally fractionated radiation therapy (CFRT) - 60 Gy/30 fractions or 66 Gy/33 fractions
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (HFRT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventionally fractionated radiation therapy (CFRT)
Number of subjects: 117
Study: 36259089

Group type: COMPARATOR
Intervention: 3 + Q12W (fixed dosing regimen with injections every 12 weeks)
Number of subjects: 249
Study: 33058884

Group type: EXPERIMENTAL
Intervention: Standard myotomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Short myotomy
Number of subjects: 100
Study: 32113878

Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg vaginally
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 34049908

Group type: EXPERIMENTAL
Intervention: Polyurethane-covered implants
Number of subjects: 321

Group type: COMPARATOR
Intervention: Textured implants
Number of subjects: 321
Study: 32578404

Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention (PPI) over 42 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 34786651

Group type: EXPERIMENTAL
Intervention: Finerenone 10 or 20 mg once daily, titrated based on serum potassium and estimated glomerular filtration rate.
Number of subjects: 5734

Group type: EXPERIMENTAL
Intervention: Finerenone (10 to 20 mg)
Number of subjects: 5734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5734
Study: 33239108

Group type: EXPERIMENTAL
Intervention: 10 μg/kg/min landiolol infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Termination of landiolol infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of landiolol
Number of subjects: 16
Study: 34333211

Group type: EXPERIMENTAL
Intervention: Nurse-led eHealth cardiac rehabilitation (NeCR)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study: 32703038

Group type: EXPERIMENTAL
Intervention: 20 mg policosanol (group A)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: 10 mg policosanol (group B)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin (group C)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: 10 mg policosanol + 20 mg atorvastatin (group D)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 294
Study: 35658002

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus Pembrolizumab (RP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 136
Study: 34533542

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine applied to the external auditory canal for 10 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with povidone-iodine not allowed to enter the external auditory canal
Number of subjects: 0
Study: 32749605

Group type: EXPERIMENTAL
Intervention: Visual inspection
Number of subjects: 114

Group type: COMPARATOR
Intervention: Computed tomography (CT) imaging
Number of subjects: 114

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 114
Study: 34995796

Group type: EXPERIMENTAL
Intervention: GIP and GLP-2 co-administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: GIP alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: GLP-2 alone
Number of subjects: 10
Study: 32504207

Group type: EXPERIMENTAL
Intervention: Small stitches technique using Monomax® 2‐0
Number of subjects: 100

Group type: COMPARATOR
Intervention: Large stitches technique using PDS II® 1 loop
Number of subjects: 100
Study: 35643280

Group type: EXPERIMENTAL
Intervention: OIT with antihistamines
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: OIT with placebo antihistamines
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: OIT
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: OIT without antihistamines
Number of subjects: 43
Study: 33883635

Group type: EXPERIMENTAL
Intervention: HIFT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HIPT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HIET
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 35